STOCK TITAN

Altimmune, Inc. - ALT STOCK NEWS

Welcome to our dedicated page for Altimmune news (Ticker: ALT), a resource for investors and traders seeking the latest updates and insights on Altimmune stock.

Altimmune, Inc. (Nasdaq: ALT) is a clinical-stage biopharmaceutical company dedicated to developing next-generation immunotherapeutics and vaccines addressing critical public health and biodefense needs. Leveraging the unique properties of its proprietary platform technologies, Altimmune is adept at swiftly designing product candidates targeting a range of diseases, including respiratory conditions, chronic infections, and cancer.

Altimmune's advanced Densigen™ T-cell platform technology is specifically designed to guide the immune system's response against complex disease targets by focusing on multiple antigens simultaneously. Another key platform, RespirVec™, uses needle-free intranasal delivery for faster and broader immunity against pathogens compared to traditional vaccines.

The company is also heavily involved in addressing obesity and liver diseases through its innovative peptide therapeutics. The lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist under development for obesity and non-alcoholic steatohepatitis (NASH). Pemvidutide has shown promising results in clinical trials, achieving significant weight loss and liver fat reduction. It has received Fast Track designation from the U.S. FDA for treating NASH, highlighting its potential to meet significant unmet medical needs.

Altimmune's pipeline also includes HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. However, the company has recently decided to cease further development on HepTcell based on Phase 2 trial findings.

Financially, Altimmune maintains a robust cash position, enabling it to advance its clinical programs. Recent financial results indicate a focused investment in research and development, ensuring continued progress in its pipeline.

Significant recent achievements include:

  • Positive top-line results from the 48-week MOMENTUM Phase 2 obesity trial of pemvidutide.
  • Ongoing Phase 2b IMPACT trial of pemvidutide in MASH with top-line results expected in Q1 2025.
  • Strong financial position with substantial cash reserves to support ongoing and future research activities.

Altimmune is poised at the forefront of developing transformative therapies for serious health conditions, potentially delivering significant advancements in patient care.

Rhea-AI Summary

Altimmune, Inc. (Nasdaq: ALT) will report its first quarter 2024 financial results and provide a business update on May 9, 2024. Altimmune management will host a conference call to discuss the financial results and business update.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.7%
Tags
conferences earnings
-
Rhea-AI Summary

Altimmune, Inc. (Nasdaq: ALT) will be represented by Dr. Scott Harris, Chief Medical Officer, at two upcoming conferences: BTIG Obesity Health Forum and GLP-1-Based Therapeutics Summit. The presentations will focus on emerging therapeutics and the use of GLP-1s in treating MASH & Fatty Liver Disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.94%
Tags
conferences
-
Rhea-AI Summary
Altimmune expresses condolences on the passing of Dr. Stephen Harrison, a key figure in the field of metabolic liver disease. Dr. Harrison's contributions and advocacy for patients will leave a lasting impact on the community.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
none
Rhea-AI Summary
Altimmune, Inc. (ALT) announces positive results from body composition study showing lean mass preservation in obesity trial. Enrollment ongoing in Phase 2b trial for pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis. Preclinical study demonstrates anti-fibrotic effect in liver fibrosis model. Company reports $198.0 million in cash, cash equivalents, and short-term investments. Webcast scheduled for March 27, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.77%
Tags
-
Rhea-AI Summary
Altimmune, Inc. (ALT) will report its Q4 and full year 2023 financial results on March 27, 2024, with a business update. A conference call will be held at 8:30 am E.T. on the same day. The call will be webcast live on Altimmune's Investor Relations website, with a replay available for three months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.86%
Tags
conferences earnings
-
Rhea-AI Summary
Altimmune, Inc. (Nasdaq: ALT) announced an abstract on pemvidutide in subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease will be presented at the NASH-TAG Conference. Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and MASH. The presentation will discuss the correlation between Pemvidutide-induced liver fat reduction and improvements in non-invasive markers of inflammation and fibrosis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.49%
Tags
Rhea-AI Summary
Altimmune, Inc. (Nasdaq: ALT) announces topline results from the 48-week MOMENTUM Phase 2 obesity trial of pemvidutide. The trial enrolled 391 subjects, achieving a mean weight loss of 15.6% on the 2.4 mg dose at Week 48. Over 30% of subjects achieved 20% or more weight loss on the same dose. Robust reductions in BMI and serum lipids and improvements in blood pressure were observed without imbalances in cardiac events, arrhythmias, or clinically meaningful increases in heart rate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.97%
Tags
-
Rhea-AI Summary
Altimmune, Inc. (Nasdaq: ALT) announced financial results and key milestones, including the 48-week results from the MOMENTUM Phase 2 obesity trial expected Q4 2023, Fast Track designation for pemvidutide in NASH treatment, and top-line results from the Phase 2 HepTcell™ trial in chronic hepatitis B expected Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.12%
Tags
-
Rhea-AI Summary
Altimmune, Inc. will report its third quarter 2023 financial results on November 7, 2023. The company will also provide a business update. A conference call will be hosted by Altimmune management at 8:30 am E.T. on November 7 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website. A replay will be available on the Investor Relations website for up to three months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.84%
Tags
conferences earnings
Rhea-AI Summary
Altimmune receives Fast Track designation from FDA for pemvidutide in the treatment of NASH
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.11%
Tags

FAQ

What is the current stock price of Altimmune (ALT)?

The current stock price of Altimmune (ALT) is $8.25 as of December 20, 2024.

What is the market cap of Altimmune (ALT)?

The market cap of Altimmune (ALT) is approximately 593.2M.

What does Altimmune, Inc. specialize in?

Altimmune specializes in developing next-generation immunotherapeutics and vaccines for public health and biodefense needs, focusing on platforms like Densigen™ and RespirVec™.

What are the main products in Altimmune's pipeline?

Altimmune's main pipeline products include pemvidutide for obesity and NASH, and HepTcell™ for chronic hepatitis B.

What is pemvidutide?

Pemvidutide is a GLP-1/glucagon dual receptor agonist under development for treating obesity and non-alcoholic steatohepatitis (NASH).

Has pemvidutide received any regulatory designations?

Yes, the U.S. FDA has granted Fast Track designation to pemvidutide for the treatment of NASH.

What is Densigen™ platform technology?

Densigen™ is a T-cell platform technology designed to direct immune responses against multiple disease targets simultaneously, particularly effective for chronic infections and cancer.

How does the RespirVec™ platform work?

RespirVec™ utilizes needle-free intranasal delivery to provide rapid and broad immunity against disease pathogens, offering a more convenient alternative to traditional vaccines.

What recent financial results has Altimmune reported?

Recent financial results show focused investment in R&D, with substantial cash reserves to support ongoing and future research activities.

What are the current clinical trials for pemvidutide?

Altimmune is conducting the Phase 2b IMPACT trial for pemvidutide in MASH, with top-line results expected in Q1 2025. The 48-week MOMENTUM Phase 2 obesity trial has already shown positive results.

What is the status of HepTcell™ development?

Altimmune has decided to cease further development of HepTcell™ based on findings from the Phase 2 trial.

Where can I find more information about Altimmune?

More information about Altimmune can be found on their official website at www.altimmune.com.

Altimmune, Inc.

Nasdaq:ALT

ALT Rankings

ALT Stock Data

593.18M
70.56M
0.79%
56.73%
32.11%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
GAITHERSBURG